Comparing a new chemotherapy drug with standard treatment for advanced breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial compares a new chemotherapy drug (called HB1801) to the standard drug docetaxel (Taxotere) for advanced breast cancer. The goal is to see if the new drug works as well and is as safe as the standard one. If you qualify, you would receive one of these treatments, which may help shrink or slow the growth of your cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have advanced (metastatic or locally advanced) breast cancer that is not removable by surgery.
- Your doctor thinks you can be treated with a single chemotherapy drug called docetaxel.
- You have at least one tumor that can be measured on a scan.
- You have not had docetaxel before for this advanced stage of breast cancer.
- Your overall health is good (able to do daily activities, expected to live at least 3 months).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental version of the chemotherapy drug paclitaxel for people with advanced breast cancer. It may help shrink tumors and slow the cancer's growth.
This trial compares two treatment options for advanced breast cancer that has low hormone receptor levels and is HER2-negative. It tests whether a combination of chemotherapy followed by maintenance therapy works better than a CDK4/6 inhibitor combined with hormone therapy. This is for people who have not had chemotherapy for their advanced disease.
This trial compares a new experimental drug (HB1801) with the standard chemotherapy docetaxel (Taxotere) for people with advanced breast cancer. It aims to see if the new drug works better or has fewer side effects.
This study tests a new combination of targeted therapies (HB1801 with trastuzumab and pertuzumab) plus chemotherapy for people with HER2-positive breast cancer that has spread or come back. It aims to see if this treatment helps shrink tumors or slow their growth.
This trial tests a new targeted drug called BL-B01D1 against standard chemotherapy in patients with advanced breast cancer that is hormone-receptor-positive (HR+) and HER2-negative, and has stopped responding to hormone treatments. The goal is to see if the new drug works better or has fewer side effects.
This trial compares two combinations of drugs given before surgery to shrink HER2-positive breast cancer. One uses a new experimental drug (TQB2102) and the other uses standard treatments. The goal is to see which works better at reducing the cancer before surgery.
Hear when a new Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.